Most drugs under development today are designed to do the same thing: inhibit the function of proteins that contribute to disease. But this strategy misses a vast therapeutic opportunity: addressing the many diseases that are caused by insufficient levels or impaired function of otherwise beneficial proteins. By developing new technology to enhance the function of these key proteins, we believe we can open up a new and diverse target space and create novel medicines for a host of hard-to-treat diseases. Our new platform harnesses the power of chemically induced proximity to create heterobifunctional molecules called enhancement-targeting chimeras (ENTACs) that can be used to enhance beneficial proteins. We will discuss the progress in the broader induced proximity space and the large opportunity in enhancing protein function with ENTACs. We will also discuss the technological challenges and gaps that we are addressing to fully realize the potential of this approach.
.png)
